Methylprednisolone pulse therapy rescued life-threatening pulmonary hemorrhage due to idiopathic pulmonary hemosiderosis

Li, Yating; Guo, Yuxiong; Cai, Liang‐Ming; Pan, Li; Duan, Meng‐Qi; Yang, Lei; Sun, Yan; Tan, Weiping; Chen, Zhuang‐Gui

doi:10.1016/j.ajem.2017.07.094

Cited by 12 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32–37 Rare treatments, such as intravenous immunoglobulin, plasmapheresis, liposteroids, and diet modification, have also been prescribed in some case reports. 38–41…”

Section: Discussionmentioning

confidence: 99%

“…[32][33][34][35][36][37] Rare treatments, such as intravenous immunoglobulin, plasmapheresis, liposteroids, and diet modification, have also been prescribed in some case reports. [38][39][40][41] The prognosis of IPH is influenced by several factors, including the time of diagnosis, early initiation of treatment, and the presence of comorbidities. 20 Historically, patients had an average survival of 2.5 years after diagnosis of IPH, but Saeed et al 3 found that 86% of patients may survive beyond 5 years.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical characteristics and prognosis of idiopathic pulmonary hemosiderosis in pediatric patients

et al. 2018

View full text Add to dashboard Cite

Objective This study aimed to analyze the clinical characteristics and prognosis of pediatric idiopathic pulmonary hemosiderosis (IPH). Methods Pediatric IPH cases that were diagnosed at West China Second University Hospital, Sichuan University between 1996 and 2017 were reviewed. Follow-up data from 34 patients were collected. Results A total of 107 patients were included (42 boys and 65 girls). The median age was 6 years at diagnosis. The main manifestations of the patients were as follows: anemia (n = 100, 93.45%), cough (n = 68, 63.55%), hemoptysis (n = 61, 57%), fever (n = 23, 21.5%), and dyspnea (n = 23, 21.5%). There were relatively few pulmonary signs. The positive rates of hemosiderin-laden macrophages in sputum, gastric lavage fluid, and bronchoalveolar lavage fluid were 91.66%, 98.21%, and 100%, respectively. Seventy-nine patients were misdiagnosed. A total of 105 patients were initially treated with glucocorticoids, among whom 102 survived and three died. Among the followed up patients, two died and 32 survived, among whom 10 presented with recurrent episodes. Conclusions The classic triad of pediatric IPH is not always present. The rates of misdiagnosis and recurrence of IPH are high. Early recognition and adequate immunosuppressive therapy are imperative for improving prognosis of IPH.

show abstract

“…32–37 Rare treatments, such as intravenous immunoglobulin, plasmapheresis, liposteroids, and diet modification, have also been prescribed in some case reports. 38–41…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Clinical characteristics and prognosis of idiopathic pulmonary hemosiderosis in pediatric patients

et al. 2018

View full text Add to dashboard Cite

show abstract

“…This is a life-threatening condition and should be treated immediately. Although the use of steroids in such a situation has been questioned (23), the benefits of this therapy cannot be ignored (24). Steroids were applied in the present case and led to clinical improvement of the patient's condition.…”

Section: Discussionmentioning

confidence: 78%

Cryobiopsy in the diagnosis of idiopathic pulmonary hemosiderosis: a case report

et al. 2019

View full text Add to dashboard Cite

“…The sample size used was following the rule of thumb formula for 5 predictors. Each predictor needs 15…”

Section: Study Populationmentioning

confidence: 99%

Expression Of S Baff, R Baff, And B Cells (Cd19+) As Potential Biomarker In Predicting Respons Treatment After Pulse Dose Metyl Prednisolone In Severe Sistemic Lupus Erithematosus

2023

JPTCP

View full text Add to dashboard Cite

Background: B cell Activating Factors (BAFF) is a co stimulatory molecule that has become the target of recent SLE treatment. Pulse dose metyl prednisolone (MEP)has been widely used and is a standard protocol in management of severe and life threathening flare up. The aim of this study is to identify whethersoluble (S) BAFF along with its receptor,(R) BAFF and B Cells (CD19+) can become predictors of pulse dose metyl prednisolone (MEP) response treatment.Method: Eighty subjects had been enrolled to this study. All subjects had SLE Disease Activity Index Score 2000 (SLEDAI 2K) score 12 or Lupus Nephritis Class 3 or 4 (WHO criteria) and decided to get pulse dose MEP. Prospective cohort study was conducted. All data as listed in SLEDAI 2k form were recorded before and after treatment. Enzyme-linked Immunoabsorbent Assay (ELISA) was used to measure S BAFF. Flowcytometry was used to measure BAFF Rand B cells (CD19+). Respons treatment was measured by SLEDAI 2K Responder Index (SRI) 50. Logistic Regression Analysis was used to identify the independent predictive factors for treatment response. Receiver Operating Characteristic (ROC) curve was used to find cut off point and Chi-sqare test to analyse proportion difference and Relative Risk (RR) to treatment response Results: There were 80 subjects enrolled in this study, all with high disease activity (mean SLEDAI 2k 30.04 ±10.8).The differerence of SLEDAI 2K score before and after pulse dose MEP was 36%.

show abstract

Methylprednisolone pulse therapy rescued life-threatening pulmonary hemorrhage due to idiopathic pulmonary hemosiderosis

Cited by 12 publications

References 25 publications

Clinical characteristics and prognosis of idiopathic pulmonary hemosiderosis in pediatric patients

Clinical characteristics and prognosis of idiopathic pulmonary hemosiderosis in pediatric patients

Cryobiopsy in the diagnosis of idiopathic pulmonary hemosiderosis: a case report

Expression Of S Baff, R Baff, And B Cells (Cd19+) As Potential Biomarker In Predicting Respons Treatment After Pulse Dose Metyl Prednisolone In Severe Sistemic Lupus Erithematosus

Contact Info

Product

Resources

About